Naveris’ flagship product is NavDx, a blood test for early detection of cancers caused by human papillomavirus (HPV) that uses proprietary patented DNA fragmentomics to distinguish viral DNA arising from cancers versus infection. The company is commercial-stage and intends to use new proceeds to advance commercialization of NavDx and to generate clinical data needed to expand into other cancer types and indications. Naveris has partnered with more than 25 medical institutions to conduct clinical studies and trials using its technology and has collaborations with biotechnology companies developing immunotherapies for HPV-related cancers. Its clinical laboratory is CLIA-certified and accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center. The company was founded in 2017, maintains facilities in Massachusetts and North Carolina, and is led by founder and CEO Piyush B. Gupta, Ph.D. Naveris develops blood-based molecular diagnostic tests to detect viral-associated cancers, led by its NavDx® assay for HPV-related malignancies. NavDx® uses proprietary circulating tumor DNA genetic fingerprints derived from technology invented at the University of North Carolina Lineberger Cancer Center. The NavDx® test was clinically validated in a 3-year longitudinal study (published in the Journal of Clinical Oncology) showing 100% negative predictive value and 94% positive predictive value for detecting recurrence of HPV-related head and neck cancer. Naveris currently offers NavDx® through its CLIA laboratory to cancer centers across the U.S. The company plans to use new financing to expand patient access, generate data to support reimbursement and inclusion in treatment guidelines, and advance product development and its pipeline for other viral-related cancers. The company is led by Founder & CEO Piyush B. Gupta, PhD, with Philip Stephens, PhD as CSO and Barry Berger, MD as CMO.

Total raised

$33M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2022